BFEC
FATE icon

Benjamin F. Edwards & Company’s Fate Therapeutics FATE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$2K Hold
700
– – ﹤0.01% 2032
2024
Q1 		$5K Buy
700
+200
+40% +$1.24K ﹤0.01% 1852
2023
Q4 		$2K Hold
500
– – ﹤0.01% 1983
2023
Q3 		$1K Hold
500
– – ﹤0.01% 1709
2023
Q2 		$2K Hold
500
– – ﹤0.01% 1666
2023
Q1 		$3K Hold
500
– – ﹤0.01% 1629
2022
Q4 		$5K Buy
+500
New +$9.39K ﹤0.01% 1567

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Benjamin F. Edwards & Company's FATE Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Fate Therapeutics (FATE) position steady in Q2 2024 at 700 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Benjamin F. Edwards & Company first reported a position in FATE in Q4 2022 and has held it in 7 quarters since. The position peaked at $5K in Q1 2024. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Benjamin F. Edwards & Company held 700 shares of Fate Therapeutics worth $2K as of Q2 2024.
  • Benjamin F. Edwards & Company left its Fate Therapeutics share count unchanged in Q2 2024.
  • Fate Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2032 holding.
  • Benjamin F. Edwards & Company first reported a position in Fate Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • Benjamin F. Edwards & Company's Fate Therapeutics position peaked at $5K in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.